- Report
- October 2022
- 286 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- June 2022
- 32 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 69 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- May 2022
- 40 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- July 2023
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- January 2025
- 132 Pages
Global
From €865EUR$950USD£734GBP
The Retinopathy Drug market is a subset of the Optical Disorders Drugs market, which includes drugs used to treat diseases of the eye. Retinopathy drugs are used to treat diseases of the retina, such as age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa. These drugs can be administered orally, topically, or by injection. Commonly used retinopathy drugs include anti-VEGF agents, corticosteroids, and photodynamic therapy.
The Retinopathy Drug market is highly competitive, with many companies developing and marketing drugs to treat retinopathy. Some of the major players in the market include Regeneron Pharmaceuticals, Novartis, Allergan, Roche, and Bayer. Show Less Read more